Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Urokinase plasminogen activator receptor-associated protein (uPARAP), also known as Endo180 or mannose receptor, C type 2, is a 180-kDa transmembrane endocytic receptor. It mediates the binding, internalization, and degradation of collagen from the extracellular matrix, playing a crucial role in tissue remodeling, particularly in the lung. uPARAP is expressed in mesenchymal cells, especially fibroblasts, and its expression can be downregulated by cytokines such as TGFβ, TNFα, and IL‑1. It represents a potential therapeutic target for modulating fibrosis and abnormal tissue remodeling processes.
Modulation of collagen turnover through receptor-mediated endocytosis and degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP).